Indication: Growth Hormone Deficiency (GHD)

A Multicenter, 24-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2 Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Idiopathic Growth Hormone Deficiency (GHD)

Sub-indication: Growth Hormone Deficience (GHD)

Study Type: Drug Study

Principal Investigator: Kupper Wintergerst, M.D.
Norton Children's Endocrinology, affiliated with the UofL School of Medicine

Sponsor: Sponsor: Lumos Pharma, Inc.

Learn more at ClinicalTrials.gov

Email for more information: NCRI-Endo@NortonHealthcare.org

Search our entire site.